Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Twist Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Twist Bioscience's regulatory disclosures and financial reporting.
TWST reported insider sales via Form 144 by Robert F. Werner. The filing lists four disposals of Common shares on ranging from $9,372.40 to $282,186.64, with share counts of 164, 4,961, 688, and 800. The transactions follow recent restricted stock vesting events on for compensation.
Company reports a Form 144 notice for proposed sales of Common Stock by an affiliate. The filing lists restricted stock vesting on 06/05/2026 and multiple dispositions by Dennis H. Cho during March–May 2026, including sales on 05/29/2026 of 14,205 shares at a reported aggregate value of $990,798.75.
The document records earlier sales of 354, 1,962, and 1,642 shares on 03/20/2026, 05/04/2026, and 05/21/2026 respectively, with aggregate values shown in the filing. The securities disposition is identified as compensation-related vesting and affiliate resale activity.
TWST reports proposed resale of 232 shares of common stock under a Rule 144 notice. The filing lists the securities as issued for Restricted Stock Vesting on 06/05/2026 and attributed to compensation.
The filing also discloses past sales by Robert F. Werner: 164 shares for $9,372.40 on 05/04/2026, 4,961 shares for $282,186.64 on 05/08/2026, 688 shares for $36,640.54 on 05/21/2026, and 800 shares for $49,987.20 on 05/26/2026.
TWST reported an insider sale filing under Rule 144 for Common Stock. The filing lists 884 shares of Common Stock to be sold on 06/05/2026 following a Restricted Stock Vesting entry. The filing also discloses three prior dispositions by Paula Green of 297, 1,116 and 1,399 shares on 03/20/2026, 05/04/2026 and 05/21/2026, respectively.
TWST director Emily M. Leproust reported multiple open-market dispositions of Common Stock. The filing lists planned sale of 2,265 shares in connection with restricted stock vesting on 06/05/2026 and a series of sales during March–May 2026, including transactions of $1,580,245.85 on 05/26/2026 and $1,633,407.46 on 05/27/2026.
The filings itemize individual sale dates and proceeds; post-transaction holdings and cash‑flow treatment are shown in the reported rows.
Twist Bioscience Corp officer Dennis Cho reported an open-market sale of 14,205 shares of Common Stock at $69.75 per share. The transaction occurred on May 29, 2026 and was executed under a pre-established Rule 10b5-1 trading plan adopted on May 7, 2025.
After this sale, Cho directly holds 120,094 Twist Bioscience shares, indicating the transaction represents only a portion of his overall ownership. Because the trade was made pursuant to a Rule 10b5-1 plan, its timing reflects a pre-planned arrangement rather than a discretionary decision based on near-term company developments.
Twist Bioscience Corp Chief Financial Officer Adam Laponis reported an open-market sale of common stock. On May 29, 2026, he sold 4,000 shares at a price of $70.00 per share. After the transaction, he directly holds 112,675 common shares. The sale was executed under a previously adopted Rule 10b5-1 trading plan dated May 8, 2025, indicating the trades were pre-scheduled rather than timed at his discretion.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported a combination of option exercise and share sales in common stock. She exercised employee stock options to acquire 16,470 shares at an exercise price of $8.82 per share, then sold 16,470 shares in multiple open‑market transactions at prices ranging from $65.3256 to $68.6141 per share. After these transactions, she directly owns 861,860 shares of Twist common stock. The sales were carried out under a pre‑arranged Rule 10b5-1 trading plan adopted on May 27, 2025.
Twist Bioscience Corp director Melissa A. Starovasnik sold 2,500 shares of Common Stock in an open-market transaction at $68.00 per share. The trade took place on May 28, 2026 and was reported as a direct ownership transaction.
Following this sale, she directly holds 22,222 shares of Twist Bioscience Corp. The filing notes that the transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 22, 2025, indicating the sale was scheduled in advance.
TWST submitted a Form 144 notice reporting proposed sales of Common Stock by an affiliate. The excerpt lists four recent sale entries: 425 shares on 03/06/2026, 354 shares on 03/20/2026, 1,962 shares on 05/04/2026, and 1,642 shares on 05/21/2026, each with the dollar amounts shown. The filing also lists routine issuer grant and ESPP vesting events dated 2022–2024.